Philippe C. Bishop, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutics
December 15 2014 - 8:30AM
Business Wire
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that
Philippe C. Bishop, MD, will join the company as Senior Vice
President, Hematology and Oncology Therapeutics. In this position,
Dr. Bishop will report to John McHutchison, MD, Executive Vice
President, Clinical Research and will have responsibility for
Gilead’s programs in oncology. Dr. Bishop will also join Gilead’s
Executive Committee.
“Philippe is an accomplished physician with an extensive
background in cancer drug development and I am very pleased to
welcome him to Gilead,” said Dr. McHutchison. “Philippe’s
appointment reflects Gilead’s ongoing commitment to further
building a leading hematology and oncology therapeutic area. His
clinical development expertise, translational focus and strategic
leadership will be of great value as we work to advance our growing
pipeline of therapies for hematological malignancies and solid
tumors.”
Dr. Bishop joins Gilead from Genentech, where he has served as
Vice President, Product Development, Oncology since 2007. At
Genentech, he was responsible for the development of Avastin,
contributed to many of the company’s oncology pipeline therapeutics
and was a member of the Roche/Genentech joint leadership team.
Prior to joining Genentech, Dr. Bishop led efforts to develop
cancer therapies at Johnson & Johnson and Sanofi-Aventis. Dr.
Bishop also previously held positions at the U.S. Food and Drug
Administration (FDA) and the National Institutes of Health
(NIH).
“Over the last several years, Gilead has worked to build strong
expertise and an extensive pipeline within the hematology and
oncology areas,” said Dr. Bishop. “I am excited to join this
dedicated, scientifically focused team, which shares my commitment
and passion for scientific innovation, and I look forward to
working with them to bring new therapeutic options to people living
with cancer.”
Dr. Bishop received his undergraduate degree from Loyola
Marymount University in Los Angeles and his medical degree from the
University of Nevada School of Medicine. He completed training in
internal medicine at the University of Washington School of
Medicine and a medical oncology fellowship at the National Cancer
Institute (NCI).
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company’s mission is to advance the care of
patients suffering from life-threatening diseases. Gilead has
operations in more than 30 countries worldwide, with headquarters
in Foster City, California.
For more information on Gilead Sciences,
please visit the company’s website at www.gilead.com, follow
Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
Gilead Sciences, Inc.Patrick O’Brien, 650-522-1936
(Investors)Amy Flood, 650-522-5643 (Media)
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024